Keyword: Nektar Therapeutics
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Takeda has paired with Nektar to work on a new immuno-oncology combination trial.
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.
UNC scientists unraveled the structure of an opioid receptor, which could allow for the design of painkillers that do not cause side effects.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.
A University of Edinburgh-led team has uncovered a mechanism in MS that prevents regulatory T cells—which prevent autoimmune activity—from developing.